These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 23849826)

  • 41. Resistance of oral squamous cell carcinoma cells to cetuximab is associated with EGFR insensitivity and enhanced stem cell-like potency.
    Ohnishi Y; Minamino Y; Kakudo K; Nozaki M
    Oncol Rep; 2014 Aug; 32(2):780-6. PubMed ID: 24926885
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Overexpression of CD85j in TNBC patients inhibits Cetuximab-mediated NK-cell ADCC but can be restored with CD85j functional blockade.
    Roberti MP; Juliá EP; Rocca YS; Amat M; Bravo AI; Loza J; Coló F; Loza CM; Fabiano V; Maino M; Podhorzer A; Fainboim L; Barrio MM; Mordoh J; Levy EM
    Eur J Immunol; 2015 May; 45(5):1560-9. PubMed ID: 25726929
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk.
    Yoshida T; Okamoto I; Okabe T; Iwasa T; Satoh T; Nishio K; Fukuoka M; Nakagawa K
    Int J Cancer; 2008 Apr; 122(7):1530-8. PubMed ID: 18033688
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1alpha.
    Lu Y; Liang K; Li X; Fan Z
    Mol Cancer; 2007 Oct; 6():63. PubMed ID: 17931419
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor.
    Kimura H; Sakai K; Arao T; Shimoyama T; Tamura T; Nishio K
    Cancer Sci; 2007 Aug; 98(8):1275-80. PubMed ID: 17498200
    [TBL] [Abstract][Full Text] [Related]  

  • 46. IgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab.
    Patel D; Guo X; Ng S; Melchior M; Balderes P; Burtrum D; Persaud K; Luna X; Ludwig DL; Kang X
    Hum Antibodies; 2010; 19(4):89-99. PubMed ID: 21178280
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Epidermal growth factor receptor targeting in cancer: a review of trends and strategies.
    Yewale C; Baradia D; Vhora I; Patil S; Misra A
    Biomaterials; 2013 Nov; 34(34):8690-707. PubMed ID: 23953842
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Protein expression signatures for inhibition of epidermal growth factor receptor-mediated signaling.
    Myers MV; Manning HC; Coffey RJ; Liebler DC
    Mol Cell Proteomics; 2012 Feb; 11(2):M111.015222. PubMed ID: 22147731
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pristimerin attenuates cell proliferation of uveal melanoma cells by inhibiting insulin-like growth factor-1 receptor and its downstream pathways.
    Xie X; Xie S; Xie C; Fang Y; Li Z; Wang R; Jiang W
    J Cell Mol Med; 2019 Nov; 23(11):7545-7553. PubMed ID: 31508890
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Expression of the serotonin receptor 2B in uveal melanoma and effects of an antagonist on cell lines.
    Weidmann C; Bérubé J; Piquet L; de la Fouchardière A; Landreville S
    Clin Exp Metastasis; 2018 Mar; 35(3):123-134. PubMed ID: 29696577
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of anti-EGFR antibody cetuximab on androgen-independent prostate cancer cells.
    Dhupkar P; Dowling M; Cengel K; Chen B
    Anticancer Res; 2010 Jun; 30(6):1905-10. PubMed ID: 20651333
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Biological activity in vitro of anti-epidermal growth factor receptor monoclonal antibodies with different affinities.
    Diaz Miqueli A; Blanco R; Garcia B; Badia T; Batista AE; Alonso R; Montero E
    Hybridoma (Larchmt); 2007 Dec; 26(6):423-31. PubMed ID: 18158788
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cytotoxic properties of radionuclide-conjugated Cetuximab without and in combination with external irradiation in head and neck cancer cells in vitro.
    Eke I; Ingargiola M; Förster C; Kunz-Schughart LA; Baumann M; Runge R; Freudenberg R; Kotzerke J; Heldt JM; Pietzsch HJ; Steinbach J; Cordes N
    Int J Radiat Biol; 2014 Aug; 90(8):678-86. PubMed ID: 24597752
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Uveal melanoma expresses NK-1 receptors and cyclosporin A induces apoptosis in human melanoma cell lines overexpressing the NK-1 receptor.
    González-Ortega A; Sánchez-Vaderrábanos E; Ramiro-Fuentes S; Salinas-Martín MV; Carranza A; Coveñas R; Muñoz M
    Peptides; 2014 May; 55():1-12. PubMed ID: 24548567
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC).
    Correale P; Marra M; Remondo C; Migali C; Misso G; Arcuri FP; Del Vecchio MT; Carducci A; Loiacono L; Tassone P; Abbruzzese A; Tagliaferri P; Caraglia M
    Eur J Cancer; 2010 Jun; 46(9):1703-11. PubMed ID: 20399639
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Gefitinib, an epidermal growth factor receptor blockade agent, shows additional or synergistic effects on the radiosensitivity of esophageal cancer cells in vitro.
    Taira N; Doihara H; Oota T; Hara F; Shien T; Takahashi H; Yoshitomi S; Ishibe Y; Shimizu N
    Acta Med Okayama; 2006 Feb; 60(1):25-34. PubMed ID: 16508686
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anti-epidermal growth factor receptor (EGFR) antibodies overcome resistance of ovarian cancer cells to targeted therapy and natural cytotoxicity.
    Gottschalk N; Kimmig R; Lang S; Singh M; Brandau S
    Int J Mol Sci; 2012; 13(9):12000-12016. PubMed ID: 23109896
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The relevance of ADCC for EGFR targeting: A review of the literature and a clinically-applicable method of assessment in patients.
    Monteverde M; Milano G; Strola G; Maffi M; Lattanzio L; Vivenza D; Tonissi F; Merlano M; Lo Nigro C
    Crit Rev Oncol Hematol; 2015 Aug; 95(2):179-90. PubMed ID: 25819749
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition.
    Burtness B; Bauman JE; Galloway T
    Lancet Oncol; 2013 Jul; 14(8):e302-9. PubMed ID: 23816296
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A novel anti-EGFR monoclonal antibody inhibiting tumor cell growth by recognizing different epitopes from cetuximab.
    Hong KW; Kim CG; Lee SH; Chang KH; Shin YW; Ryoo KH; Kim SH; Kim YS
    J Biotechnol; 2010 Jan; 145(1):84-91. PubMed ID: 19828124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.